CTTH - CTT Pharma Starts Product Development
(TheNewswire)
Tampa, Florida, United States - The Newswire - November 30, 2022 - CTTPharmaceutical Holdings, Inc (OTC:CTTH) has started the development ofour three new oral products. CTT is using it's patented technology todevelop chewing gum, gummies and capsules and anticipate completion ofthese new oral products by the end of Q4 2022. CTT will immediatelystart testing our new products for stability and efficacy.
Ryan Khouri, CEO of CTT Pharma stated, I’m excited to seedevelopment start and look forward to the completion of these newproducts. CTT will continue to update shareholders as more newsbecomes available.
About CTT Pharma
CTT has patents granted and pending in over 50 countries giving CTT aglobal reach with our fast drug delivery technology. These patentsprotect our dissolvable strips and many other oral products. CTT’sdissolvable strips enter the bloodstream once dissolved in the mouthbypassing the lungs and digestive tract, allowing for betterabsorption, faster onset, as fast as an injection, and the ability tocombine APIs.
CTT successfully received Health Canada approval for our dissolvablestrips and sold out our initial product in weeks. CTT can utilize itstechnology into many APIs such as Nicotine, CBD, Caffeine, Vitaminsand Pharmaceuticals to name a few.
CTT Pharma – 813-606-0060
Copyright (c) 2022 TheNewswire - All rights reserved.